Wall Street Daily

Is This the New Martin Shkreli?

Remember Martin Shkreli’s sinister move back in 2015?

The biotech entrepreneur raised the price of Daraprim by over 5,000% — and was immediately dubbed “the Most Hated Man in America.”

Well, a new contender just entered the ring.

Avondale Pharmaceuticals jacked up the price of Niacor by over 800% last month.

Previously, 100 tablets of Niacor — a vitamin B3 drug that’s commonly prescribed to treat high cholesterol — went for $32.46. Yet Avondale quietly raised the price to $295 in November.

This isn’t the company’s only infraction, either.

Avondale has also increased the price of respiratory drug SSKI by 2,469%.

So who’s pulling the strings this time?

The Financial Times has narrowed it down to executive Mark Pugh…

“Avondale has no website or online presence and lists its address as a business park in Alabama, according to state records. The registered agent for the company is Acrogen Pharmaceuticals, which was set up in 2016 by Mark Pugh. Mr. Pugh has held several executive roles in the drugmaking industry, sometimes at companies that have implemented very sharp price increases.”
— Financial Times

Will Pugh suffer the same fate as Shkreli?

Only time will tell.

Either way, the United States pharmaceutical industry is clearly in dire need of regulatory oversight.

Of course, there are certain sectors that benefit from a lack of government regulation.

Bitcoin, for instance, has enjoyed a solid upward growth trajectory as the world’s first decentralized currency.

The cryptocurrency has now jumped over $17,000. And there appears to be no end in sight.

Now, if you’ve invested in or are planning to invest in bitcoin or other cryptocurrencies…

You MUST click here and see what could be the biggest shock of 2018.


Online Gambling Market on 11-Year Growth Trajectory

Believe it or not, online gambling is a $40 billion industry and growing fast. The industry’s expansion is absolutely insane. Take a look at this chart to see what I mean. It’s just further proof that when charts go insane, profits aren’t far behind… Read more »


The Investing Lesson of Mastodons

On the heels of Amazon’s acquisition of Whole Foods, investors are convinced that every retailer is in Amazon’s cross hairs. Not so fast! Bespoke Investment Group recently compiled an “Amazon Survivors” Index, which includes retailers they believe can survive Amazon’s onslaught. Read more »


The Hunt for Survivors in an Amazon-Dominated World

Monsanto was recently in the headlines again because a key ingredient in its Roundup weed killer, glyphosate, is now officially “known to cause cancer.” Here are a few other perverse inventions the company has engineered. Read more »


Killer Robot Panic

A consortium of 116 industry insiders decided to sign a loose agreement — one that bans the use of lethal autonomous weapons (or “killer robots”). Imagine a world where gunpowder was never allowed to be developed. Or a world where nuclear fission was deemed too dangerous. Are such mandates a good idea? Or do they thwart the natural progress of innovation — and, most importantly, investment opportunities? Read more »